Primatene Mist Availability Not “Essential,” Advisory Panel Says
This article was originally published in The Tan Sheet
Executive Summary
Questions about the appropriateness of asthma for OTC treatment led to an FDA advisory panel vote in favor of removing Wyeth's Primatene Mistfrom the market during a Jan. 24 meeting in Bethesda, Md
You may also be interested in...
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Generics manufacturer Armstrong Pharmaceuticals now has until the end of 2011 to remove Primatene Mist and private-label epinephrine inhalers from the market
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Generics manufacturer Armstrong Pharmaceuticals now has until the end of 2011 to remove Primatene Mist and private-label epinephrine inhalers from the market
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Generics manufacturer Armstrong Pharmaceuticals now has until the end of 2011 to remove Primatene Mist and private-label epinephrine inhalers from the market